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A hybrid pharmacokinetic/pharmacodynamic (PK/PD) model with extended-release (ER) process and
target mediated drug disposition (TMDD) was developed for exenatide ER to account for its complex
absorption process and glucagon-like peptide 1 receptor (GLP-1R)-mediated non-linear PK behaviors
along with its inﬂuences to fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c). Using hybrid
PK/PD model, simulations were done to explore the potential dosing regimens which could achieve
likelihood of more pharmacodynamic exposure with respect to FPG and HbA1c over a much shorter
period compared with the currently used treatment protocol. The mean PK/PD data about exenatide
ER for type 2 diabetes mellitus (T2DM) were digitized from the publications, and the hybrid PK/PD
model was performed using the Monolix 4.3 program. The plasma concentration-time and FPG/
HbA1c-time proﬁles for exenatide ER subcutaneously administrated to patients with T2DM were
well described by this hybrid model. Monte Carlo simulation was applied to mimic the PK proﬁles
when higher loading dose 7.5 and 5.0 mg exenatide ER were subcutaneously administrated with
different dosing intervals at the ﬁrst 3 weeks of 30-week treatment. Two potentially optimizing
schedules could improve the likelihood of achieving much more FPG and HbA1c exposures than
currently used clinical treatment protocol.
© 2015 Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.1. Introduction
Type 2 diabetes mellitus (T2DM) is characterized by the loss of
pancreatic b cell function, insulin resistance and progressive hy-
perglycemia, leading to increased risk of cardiovascular disease and
development of complications such as early stages of diabetic ne-
phropathy with micro-albuminuria (1,2,3). An increase in the un-
derstanding of the role of GLP-1R has provided additional
therapeutic options in the treatment of T2DM. Several recent arti-
cles provide a review of the efﬁcacy proﬁles of GLP-1R agonistacological Society.
r B.V. on behalf of Japanese Pharmexenatide IR (4,5,6,7,8) and exenatide ER based on the emerging
results from the randomized clinical trials (4,9,10,11,12).
Exenatide is an incretin hormone mimetic with multiple
glucose-regulation actions, including enhancement of glucose
dependent insulin secretion, suppression of inappropriately
elevated glucagon secretion, slowing of the gastric emptying, and
reduction of food intake and body weight (9,13). Exenatide ER is a
long-acting release formulation for subcutaneous injection in
patients with T2DM, which utilizes the poly lactide-co-glycolide
(PLGA) polymeric matrix (14) to make the active ingredient
gradually release in subcutaneous tissue. In two head-to-head
clinical trials, exenatide ER resulted in signiﬁcantly greater im-
provements in glycemic control than exenatide given twice a day,
with no increased risk of hypoglycaemia and similar reductions in
bodyweight (4,15). Another 26-week, 240-subject sub-studyacological Society.
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cemic control with less nausea, compared with exenatide imme-
diate release (IR) in patients with T2DM (16). Given the superior
efﬁcacy and comparable safety proﬁle of exenatide ER compared
with exenatide IR, exenatide ER has become the treatment of
choice for T2DM.
The clinical trial (11) of exenatide ER demonstrated that a
weekly dosing regimen would result in sustained steady state
regulation of FPG and postprandial glucose (PPG) levels, and
indicated that 2.0 mg was the optimal dose of exenatide ER in
chronic treatment process. However, this optimal dose came
from the dose-escalating clinical trial where exenatide ER was
subcutaneously administrated at several dose levels, which
needed a lot of the manpower, the material resources and the
time. PK/PD modeling and simulation as an applied science tool
(17) can be used to provide answers on efﬁcacy and safety of
exenatide ER faster and at a lower cost, since the PK/PD link
model will quantitatively depict the relationship of sustained-
release formulation exposure and clinical response. PK/PD
model quantitatively describes the process of drug behaviors and
actions in vivo, helps people to better understand drug efﬁcacy
and safety, and has become a powerful tool to optimize dosing
regimen in the clinical treatment. Regarding the existing PK and
efﬁcacy analysis of exenatide ER, several clinical studies only
descriptively investigated the relationships between drug expo-
sures and efﬁcacy results. However, this kind of descriptive
analysis did not account for the complex interaction process
between drug exposure of sustained release formulation and
clinical efﬁcacy, and the existing optimal dosing regimen of
exenatide ER was only obtained from dose-escalation study at
several dose levels in clinical trial.
Target mediated drug disposition (TMDD) (18,19) is a common
phenomenon where drug disposition is inﬂuenced by capacity-
limited binding to a target, resulting in dose-dependent events,
such as a decrease in drug clearance with increasing dose level
(20,21). Recombinant human erythropoietin (rHuEPO) exhibited
TMDD where its disposition and anti-anemic activity associated
with chronic renal failure and chemotherapy were mediated by
its interaction with EPO receptor (22). The TMDD for receptor
mediated endocytosis via GLP-1R as the primary mechanism was
investigated by building mechanism based PK/PD model of exe-
natide (18). Mechanism-based PK/PD model can explicitly ac-
count for the full time courses of both drug concentrations and
effects simultaneously. In contrast to empirical models,
mechanism-based models are more powerful at aiding under-
standing of the underlying kinetic mechanism and proposing
likely mechanisms of action for exenatide ER. In this study re-
ported here, a hybrid PK/PD MBMA further provides a lear-
ningeconﬁrming paradigm of new formulation development
with PLGA material as sustained release matrix and with the
beneﬁts of a fewer number of trials/patients.
Therefore, the objective of this MBMA was to conduct a hybrid
extended release process and GLP-1R mediated PK/PD model for
exenatide ER following subcutaneous administration in patients
with T2DM receiving chronic treatment to quantitatively charac-
terize the time-courses of exenatide plasma concentrations and
efﬁcacy results. Owing to sustained release process of exenatide ER,
exenatide molecules could slowly circulate into plasma and the
plasma concentrations of exenatide approached the steady state
until 6e7weeks. This was necessary in order to shorten the time for
plasma concentrations of exenatide to reach the steady state and to
improve the glycaemic control, the currently used dosing regimen
of exenatide ER in the clinic would be optimized through hybrid PK/
PD model.2. Methods
Data sources: Exenatide ER studies were identiﬁed from sys-
tematic computer searches in MEDLINE, EMBASE, and on http://
www.ClinicalTrials.gov. The medical subject heading terms and
text words from electric databases included efﬁcacy, pharmacoki-
netics, pharmacodynamics, FPG, HbA1c, T2DM and clinical trial.
The mean plasma concentrations and efﬁcacy data (FPG and
HbA1c) of exenatide ER in human were captured by computer
digitization from previous publications. For convenient model
development, all concentration data with picogram per milliliter
units (pg/mL) were converted to data with picomole per liter units
(pmol/L) and doses were converted to pmole by using the exe-
natide molecular weight of 4186.6 g/moL, and all efﬁcacy data
were converted to ratios of FPG and HbA1c to their own baseline
values (BL) (FPG/FPG_BL and HbA1c/HbA1c_BL) in ﬁnal model
development.
Included studies were randomized controlled trials that
analyzed the pharmacokinetics and efﬁcacy of exenatide ER in the
reductions of FPG and HbA1c for T2DM patients, irrespective of
background medications. Two independent reviewers extracted
aggregated data from all selected studies.
Software: Monolix software version 4.3 (http://software.
monolix.org) was used for the non-linear mixed-effect (23,24)
PK/PD model development of exenatide ER. Parameters of PK/PD
model were estimated by computing the maximum likelihood
estimator using the stochastic approximation expectation maxi-
mization (SAME) algorithm method coupled with Markov Chain
Monte Carlo (MCMC). The model building processes were guided
by visual inspection of goodness of ﬁt (GOF) and change of2 times
the log likelihood (OFV), Akaike Information Criteria (AIC) and
Bayesian Information Criteria (BIC). The ﬁnal model was mainly
appreciated by the prediction distribution. Several graphical plots
were also generated using R version 3.1 (The R Foundation for
Statistical Computing, http://www.R-project.org), RStudio version
0.98 (http://www.rstudio.com), lattice (http://lattice.r-forge.r-
project.org) and latticeExtra (http://latticeextra.r-forge. r-project.
org) packages.
PKModeling: In the present study, the sustained release process
associated with exenatide ER from the subcutaneous site and PLGA
matrix was mainly investigated, which could be viewed as different
fractions of exenatide injected into a series of segments and each
segment could be described as a single compartment with linear
transfer kinetics before drug reached absorption compartments.
Therefore, release of exenatide from injection site and formulation
(microspheres utilizing PLGA as extended release material) was
characterized by a series of transit compartments, as seen in Fig. 1.
Dose (amtDose) was amount of exenatide ER in virtual dosing
compartment (Dose (s.c)) of subcutaneous injection site. When the
dose was injected into subcutaneous tissue, different quantity of
drug amount was ﬁrst distributed into different compartments by
means of different absorption fractions (F1eF3), and the amount of
drug in each compartment was subsequently transferred from the
prior compartment to next compartment through the ﬁrst-order
rate constant (ktr). Block a1ea4 represented 4 distributing com-
partments into which exenatide was released from PLGA excipient
and injection site. Once the exenatidewas released from the PLGA to
plasma circulation, the distribution and elimination of exenatide
were independent of dosage form and injection site. However,
distribution of exenatide was associated with capacity-limited
binding to a target (18), a two-compartment model with 4 transit
absorption compartments and target mediated disposition was
applied to characterize the PK behaviors of exenatide ER in humans.
Differential equations used to describe plasma PK are shown below:
Fig. 1. Schematic of the hybrid model composing of 4 transit compartments (a1ea4) and 1 absorption compartment (a5) depicting the complex absorption process of exenatide ER,
and 2 indirect response models for describing FPG and HbA1c inhibition over time. The PK part of exenatide is denoted by a1ea7, GLP-1R and GLP-1R*a6, and PD part of exenatide is
denoted by FPG (FPG/FPG_BL) and HbA1c (HbA1c/ HbA1c_BL). Solid lines with arrows represent the transit (ktr), absorption (ka), elimination (CL), or two-compartment with target
mediated drug distribution (Q, V1, V2, ksyn, kdeg, koff, kon and kint), or indicate the conversions of the responses (kinG and koutG for FPG; kinHb and koutHb for HbA1c). Dashed
lines with arrows mean the drug molecules straightly diffuse into 4 transit compartments (F1eF3). Black boxes (S1 and FPG) mean the inhibitory effect being exerted by the
connected factors.
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dt
¼ ktr$a1 (1)
da2
dt
¼ ktr$ða1 a2Þ (2)
da3
dt
¼ ktr$ða2 a3Þ (3)
da4
dt
¼ ktr$ða3 a4Þ (4)
da5
dt
¼ ktr$a4 ka$a5 (5)
da6
dt
¼ ka$a5 Q
V1
$a6 CL
V1
$a6þ Q
V2
$a7 kon$a8$a6
þ koff $a9$V1 (6)da7
dt
¼ Q
V1
$a6 Q
V2
$a7 (7)
da8
dt
¼ ksyn kdeg$a8 kon$a8$a6=V1þ koff $a9 (8)
da9
dt
¼ kon$a8$a6=V1 koff $a9 kint$a9 (9)
The initial conditions of above differential equations (Eqs.
(1)e(4) and (8)) are deﬁned as
a1 0 ¼ ð1 F1 F2 F3Þ$amtDose
a2 0 ¼ F1$amtDose
a3 0 ¼ F2$amtDose
Table 1
The data used in this PK/PD model based meta-analysis were digitalized from the
published papers.
Doses
for ER
FPG (mg/dl) HbA1c (%) Treatment
period
(weeks)
Duration
of T2DM
(years)
Patients
(N)
Literature
2.0 mg 159.2 ± 28.1 7.3 ± 0.8 10 5.0 ± 4.0 9 (12)
2.0 mg 167.1 ± 7.3 8.3 ± 0.3 15 4.5 ± 4.0 15 (11)
2.0 mg 163 ± 39.6a 7.4 ± 1.2 10 3.1 ± 3.1 25 (10)
2.0 mg 172.8 ± 43.2a 8.3 ± 1.0 30 7.0 ± 6.0 148b (4)
0.8 mg 145.0 ± 16.5 7.4 ± 0.7 10 6.0 ± 6.0 10 (12)
0.8 mg 185.6 ± 12.2 8.6 ± 0.3 15 4.5 ± 4.0 16 (11)
Values are expressed as mean ± SE.
a Data (mg/dl) were converted from mmol/L through multiple 18 times in
literatures.
b 148 patients participated in the ITT (2.0 mg exenatide ER once a week), of which
129 patients completed the pharmacokinetics study and 148 patients completed the
pharmacodynamics study.
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a8 0 ¼ ksyn=kdeg
where a1ea4 are the amount of exenatide in each segment
compartment; a5 is the amount of exenatide in absorption
compartment; V1 and V2 are the volumes of the central and pe-
ripheral compartments, respectively; CL and Q represent the
elimination and inter-compartment clearances, respectively; a6
and a7 are the amount of exenatide in central and peripheral
compartments, respectively; a8 and a9 represent the amount of
GLP-1receptors and GLP-1R*a6 complex, respectively (Fig. 1). The
free exenatide in plasma can bind to GLP-1R with a second-order
rate constant (kon) to form drug-receptor complex (GLP-1R*a6),
distribute to and from tissues (a7), and be directly eliminated (CL).
The GLP-1R*a6 can dissociate at a ﬁrst-order rate (koff) and can be
internalized and degraded (kint). The GLP-1R is synthesized at a
zero-order rate (ksyn) and degraded at a ﬁrst-order rate (kdeg)
with the relationship of Rtot¼ ksyn/kdeg, a1_0ea4_0 represent the
initial amount of exenatide in a1ea4 compartments and a8_0
represents GLP-1 R amount when the time is zero.
PD Modeling: Two PD models including effects of exenatide ER
on FPG as well as incorporating FPG/ HbA1c inter-regulations (25)
are developed as depicted in Fig. 1. The model equations were
ﬁtted to FPG and HbA1c data from all treatments simultaneously.
The modeling for drug effects was based on the fact that the FPG
and HbA1c were produced with a zero-order input rate and dissi-
pated with a ﬁrst-order output rate. The dynamics of efﬁcacy (FPG
and HbA1c) were characterized by two indirect response models
with the zero-order input rate constants (kinG and kinHb) and the
ﬁrst-order output rate constants (koutG and koutHb). FPG inhibited
HbA1c production with an inhibitory factor FPG.
dFPG=FPG BL
dt
¼ kinG koutG$ð1þ S1Þ$FPG=FPG BL (10)
dHbA1C=HbA1C BL
dt
¼ kinHb$FPG=FPG BL
 koutHb$HbA1C=HbA1C BL (11)
S1 ¼ EmaxG$a6=V1=ðEC50G þ a6=V1Þ (12)
The baseline conditions (time was zero) for above differential
equations (Eqs. (10) and (11)) are deﬁned as:
FPG 0=FPG BL ¼ kinG=koutG
HbA1C 0=HbA1C BL ¼ kinG$kinHb=ðkoutG$koutHbÞ
where EmaxG is themaximumpossible inhibition of FPGproduction
by exenatide; EC50G is the plasma concentrations of exenatide
causing one-half maximum inhibition for FPG production; S1 rep-
resents the standard non-linear Hill equations; FPG/FPG_BL and
HbA1c/HbA1c_BL represent effects of exenatide on FPG and HbA1c
change from initial condition states, respectively, and FPG_0/FPG_BL
to HbA1c_0/HbA1c_BL represent the initial values of Eqs. (10) and
(11). The units of individual PD parameters are listed in Table 2.
Statistical model: The between variability of selected PK/PD
parameters was described by the exponential and additive models.
The below exponential and additive models are used to describe
the between variability of selected PK/PD parameters:Pi ¼ Ppop$exp

hpi

(13)
Pi ¼ Ppop þ hpi (14)
where individual parameters for exponential model mainly include
F1eF3, ka, ktr, kon, koff, ksyn, kdeg, kin and kout, while individual
parameters for additive model mainly include CL, Q, V1, V2, EmaxG
and EC50G; Pi is the individual parameter value, Ppop is its typical
population value, and hPi is an independent random variable nor-
mally distributed with zero mean and standard deviation upi.
The exponential models of the residual error were applied to
drug serum concentrations, FPG and HbA1c data:
Y ¼ bY $expðεÞ (15)
where Y is the observation, bY is the corresponding model predic-
tion and ε is assumed to be an independent and normally distrib-
uted randomvariable with the zero mean and standard deviation s.
Modeling strategy: Several different PK models were evaluated
as base structural models, and two-compartment model with
hybrid ER process and target mediated drug disposition was the
best appropriate to be selected to link PD models. A simultaneous
PK/PDmodeling was performed to characterize the time-courses of
exenatide plasma concentrations and efﬁcacy results following
subcutaneous administration to patients with T2DM. The popula-
tion approach was used to describe the PK/PD data (PK, FPG and
HbA1c) of exenatide ER and to obtain population parameter esti-
mates together with the inter-trial variability.
Model internal validation: The adequacy of ﬁtting was exam-
ined by basic GOF diagnostics, which included plots of normalized
prediction distribution error (NPDE) (26) vs. time and individual
study prediction, and plots of population study prediction (PRED)
and individual study prediction (IPRED) vs.mean observation (DV).
Other diagnostics were the OFV and the precision of the parameter
estimates.3. Results
Human PK/PD data: A literature search focusing on exenatide
ER PK/PD studies was performed, and 4 publications (4,10e12)
were deemed appropriate for inclusion and were utilized to digi-
talize the plasma concentrations and efﬁcacy data for ﬁnally com-
binedmodel development. Table 1 provides a summary of available
data involving the effects of exenatide ER on the FPG and HbA1c in
randomized clinical trials.
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cacy assessments and were exposed to treatments and completed
the therapies over time of 10e30 weeks, and 129 of 223 partici-
pated patients completed the pharmacokinetic studies in clinical
trials. PK/PD data of these subjects ﬁnally composed of the dataset
for model development. For all studies, the study protocols were
approved by the local ethics and research committees, and written
informed consent forms were obtained from all patients enrolled in
PK/PD studies.
Pharmacokinetics: The plots of observed and ﬁtted exenatide
concentrations over time after S.C administration at multiple
dosing regimens are presented in Fig. 2A, and PK parameters are
summarized in Table 2. After subcutaneous injection of dose, exe-
natide concentrations increased rapidly due to the transient burst
release, reaching initial peaks about 2.5 h (11), which was greater
than median Tmax 1.5 h of 10 mg subcutaneous dose of the twice-
daily exenatide IR formulation in clinical studies (6). The drug
molecules weakly binding to surface of PLGA microsphere might
ﬁrst dissolve and distribute into plasma circulation (27), leading to
transient increase of plasma exenatide concentrations. Owing to
sustained release of exenatide in the inside of PLGA microsphere,
exenatide concentrations increased again after 1 week and
approached steady state after 6e7 weeks (11). The proposed hybrid
PK model with 4 transit compartments and GLP-1R mediated drug
disposition accurately capture the release behaviors of exenatide
from PLGA material and injection site, and adequately describe PK
proﬁles of different clinical trials. Prediction distribution results
demonstrated that the proposed PK model could predict the exe-
natide concentrations closely and most of the observed concen-
trations fell inside the 95% prediction intervals.Table 2
PK/PD model parameter estimates for exenatide ER in patients with T2DM.
Parameter Deﬁnition
Pharmacokinetic parameters
F1 Fraction of exenatide in the 2th transit compar
F2 Fraction of exenatide in the 3th transit compar
F3 Fraction of exenatide in the 4th transit compar
ktr(1/h) Transit rate constant
ka (1/h) Absorption rate constant
CL/F(L/h) Central compartment clearance
Q/F(L/h) Inter-compartment clearance
V1/F(L) Central volume of distribution
V2/F(L) Peripheral volume of distribution
kon (1/pmol/L/h) Second-order receptor binding rate constant
koff(1/h) First-order dissociation rate constant
ksyn(pmol/L/h) GLP-1R synthesis rate constant
Kint (1/h) GLP-1R complex internalization rate constant
Kdeg(1/h) GLP-1R degradation rate constant
Pharmacodynamic parameters (FPG and HbA1c)
KinG(1/h) Zero-order production rate constant for FPG
KoutG(1/h) First-order loss rate constant for FPG
KinHb(1/h) Zero-order production rate constant for HbA1c
KoutHb(1/h) First-order loss rate constant for HbA1c
EmaxG Maximum inhibition response for FPG
EC50(pmol/L) Concentration for 50% of FPG effect
Secondary parameters
FPG_0/FPG_BL Proportion of FPG in baseline of FPG value
HbA1c_0/HbA1c_BL Proportion of HbA1c in baseline of HbA1c valu
GLP-1R_0 (pmol/L) Receptor concentration at steady state
KD (pmol/L) The equilibrium dissociation constant (Koff/ko
EmaxHb Maximum inhibition response for HbA1c
Error model parameters (exponential error)
a_PK scaling factor for PK data
a_FPG scaling factor for FPG data
a_HbA1c scaling factor for HbA1c data
BL ¼ baseline value; R.S.E ¼ Relative standard error of the estimate calculated as (SE/Estim
ITV ¼ inter-trial variability; EmaxHb was calculated from Eqs. (10) and (11) when the reA majority of PK parameters were estimated with good preci-
sion (%R.S.E  30%) except for F2 at 59%. Exenatide distributionwas
described with volume V1/F and V2/F corresponding to 9.4 L and
31.2 L, respectively, and clearance was 7.92 L/h for CL/F in clinical
trials. The volume V1/F for exenatide ER was similar to the reported
value (9.8 L, converted from 0.14 L/kg (70 kg)) (28), while the vol-
ume (V2/F, 31.2 L) for exenatide ER was similar to the volume (V2/F,
28.3 L) of exenatide IR (results not shown here). The clearance
(7.92 L/h) for exenatide ER was slightly higher than that (6.06 L/h,
calculated from parameter (central compartment volume Vc
(111 ml/kg) and central compartment elimination rata constant kel
(0.013/min)) of exenatide IR (18).
Although TMDD model (18) adequately described the PK pro-
ﬁles of exenatide IR for humans, total receptor content (GLP-1R_0)
was unable to accurately obtain. In the present hybrid model, ksyn
and kdeg were estimated with small R.S.Es, and total receptor
content of GLP-1R was 3.57 nmol/L which was slightly lower than
5.2 nmol/L of plasma GLP-1 concentration for rats (28). Likewise,
the equilibrium dissociation constant KD was 1.65 nmol/L calcu-
lated from parameter estimates (kon and koff) which had reason-
able precisions. Kon (0.00423 pM1/h, RSE ¼ 27%) was 5.9-fold
lower than reported value (0.025 pM1/h, CV% ¼ 351%), koff (7/h,
RSE ¼ 16%) was 4.9-fold lower than reported value (34/h, CV
% ¼ 399%), and kint (3.01/h, RSE ¼ 11%) was 14.6-fold higher than
reported value (0.206/h, CV% ¼ 587%) in publication (18).
Pharmacodynamics: The mean PD data for FPG and HbA1c
were ﬁtted simultaneously by hybrid model. A majority of PD pa-
rameters were also estimated with good precision (%R.S.E  29%),
and the estimated parameters and their %R.S.Es for mean FPG and
HbA1c data modeling are presented in Table 2.estimate %R.S.E %ITV
tment 0.0263 28 18.6
tment 0.00492 56 4.69
tment 0.252 30 69.4
0.00235 8 18.2
9.29 18 8.63
7.92 6 36.7
4.68 15 0.239
9.4 8 48.1
31.2 14 3.36
0.00423 27 0.131
7 16 0.0154
768 14 7.17
3.01 11 1.69
0.215 18 11.7
0.0077 29 2.89
0.00786 29 0.207
0.00151 12 0.018
0.00146 12 4.23
0.35 3 0.658
15 10 0.186
0.98
e 1.01
3572.1
n) 1654.8
0.249
0.293 7
0.055 7
0.023 12
ate); EC50 ¼ drug concentration producing 50% of Emax; Emax ¼maximum effect;
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Fig. 2. Prediction distribution for mean plasma exenatide concentrations (A), mean change in FPG levels (B) and mean change in HbA1c levels (C) after multiple injections of
exenatide ER. The dashed line represents the median model prediction and the solid lines represent the 95% conﬁdence interval of the prediction; the open circles represent the
observed mean plasma concentrations (A), ratios of FPG/FPG_BL (B) and ratios of HbA1c/HbA1c_BL (C).
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S.C administration of exenatide ER in patients with T2DM are
shown in Fig. 2B. An indirect response model appropriately
described the relationship between FPG levels and exenatide con-
centrations, with a population estimated exenatide concentration
that produced 50% of the EmaxG (15 pmol/L or 62.8 pg/mL for
EC50G) and amaximum glucose reduction response (35% of baseline
for EmaxG), and the initial value of FPG_0/FPG_BL was estimated
98% in this model. Zero-order production rate constant and ﬁrst-
order loss rate constant for FPG were 0.0077/h and 0.00786/h,
respectively. The estimates of parameter EmaxG and KoutG were
similar to 36.6% and 0.00542/h reported by Naik et al. (25),
respectively. The estimated ﬁrst-order loss rate constant for FPG
corresponds to a half-life of 3.7 days. Using this estimated value, the
steady-state reduction in FPG was predicted to be achieved after
approximately 18.4 days or 2.6 weeks.
Observed HbA1c over time proﬁles after multiple S.C admin-
istration of exenatide ER in patients with T2DM are shown in
Fig. 2C. An indirect response model best described HbA1c re-
ductions, the initial value of HbA1c_0/HbA1c_BL was estimated
101% in this model. Zero-order production rate constant and ﬁrst-order loss rate constant for HbA1c were 0.00151/h and 0.00146/h,
respectively. The estimate of koutHb was about 3-fold 0.000502/h
reported by Naik et al. (25) and was similar to 0.00123/h (0.207/
weeks) reported by Gibbs et al. (29). The estimated ﬁrst-order
loss rate constant for HbA1c corresponds to a half-life of 2.8
weeks. Using this estimated value, the steady-state reduction in
HbA1c was predicted to be achieved after approximately 14.1
weeks.
Model validation: For internal evaluation, the combined diag-
nostic plots for the quantitative model of PK, FPG and HbA1c are
shown in Fig. 3. GOF plots suggested that the hybrid PK/PD model
ﬁtted the data well. The plots of NPDE vs. time and NPDE vs. pre-
dictions showed a random and symmetric distribution around x-
axis (4 to 4) and were centered to zero (Fig. 3A and B). The hollow
circles of DV vs. either the PRED or IPRED distributed around x ¼ y
(Fig. 3C and D).
One clinical trial study example for mean PK/PD data pre-
diction: PK/PD prediction of mean clinical data taken from one
study (11) with 0.8 and 2.0 mg doses for exenatide ER is shown in
Fig. 4. The population model ﬁtted the data well and described the
observed values of PK data for two doses (Fig. 4A for left panel and
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Fig. 3. Diagnostic plots for ﬁnally integrated PK/PD model: normalized prediction distribution error (NPDE) vs. time and individual study prediction (IPRED) (A and B); population
study prediction (PRED) and individual study prediction (IPRED) vs. mean study observation (DV) (C and D).
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(Fig. 4B for left panel and for right panel), and observed values of
HbA1c data for two doses (Fig. 4C for left panel and for right
panel).
Optimizing dosing regimens for patients with T2DM: For
present dosing regimen study, two schedules have the same
treatment durations with 30 weeks. Patients undergo 2-week
higher-loading doses at the ﬁrst 3 weeks, and then begin the
assigned treatment with 2.0 mg exenatide ER once weekly for the
remainder of 30-week assessment period.
Through several model simulations, two schedules were more
appropriate to be selected to guide clinical application of exenatide
ER,whichmainly included 7.5mge5.0mge 0.0mge2.0mge2mg
onceweekly for 0the 1ste 2nde 3rde 29thweek (schedule 1) and
7.5mge0.0mge5.0mge2.0mgonceweekly for 0the1ste 2nde
3rde29thweek (schedule 2), and theoptimized schedule results for
exenatide ER are shown in Fig. 5. The simulation results demon-
strated that these two schedules had similar PK, FPG and HbA1c
proﬁles for 30-week treatment, and no signiﬁcant differences were
seen in PK, FPG and HbA1c data between schedules by comparison
with PK population prediction of 2.0 mg exenatide ER. The time
reaching the steady state concentrations of exenatide ER (71.7 pmol/L) or reaching EC80 (60pmol/L) can be shortenby8weeks or 6weeks
for schedule1 (Fig. 5A); whereas the time reaching 71.7 pmol/L or
reaching 60 pmol/L can be shorten by 12 weeks or 4 weeks for
schedule 2. At the same time, the PD (FPG and HbA1c) proﬁles in
both schedules have also been improved by comparison with pop-
ulation PD prediction of 2.0 mg in Fig. 5B and C.
4. Discussion
We have performed a hybrid extended release process and in-
tegrated target mediated PK/PD MBMA that descried the exposure
and GLP-1R-binding relationship in patients treated by once-
weekly dosing of a long-acting release formulation, exanatide ER.
The hybrid PK/PD model was used to quantify the extended release
process of exenatide ER and dynamic interaction of exenatide
binding to GLP-1R, and this model adequately ﬁtted observedmean
clinical data including PK and efﬁcacy results, as illustrated in
Fig. 2AeC. To our knowledge, this is the ﬁrst hybrid extended
release process and GLP-1R mediated PK/PD study, which simul-
taneously investigates complex release behavior, GLP-1R mediated
disposition and efﬁcacy results of exenatide once weekly in T2DM
patients. The present MBMA approach used in this study allows for
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Fig. 4. Prediction distribution for one clinical study of mean plasma exenatide concentrations (A), mean change in FPG levels (B) and mean change in HbA1c levels (C) after multiple
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regimens of exenatide ER, thus the proposed hybrid model for
exenatide ER holds great potential in its application toward the
improvement of glycemic control for treatment of T2DM patients.
Pharmacokinetics: Exanatide ER, once-weekly dosing formu-
lation, contained active ingredient of exenatide encapsulated in
microspheres mainly composed of medical-grade biodegradablepolymer PLGA (30), which controlled exenatide plasma concen-
trations to reach the therapeutic range by 2 weeks and to keep
steady state by 6e7 weeks (11). It can be seen that PLGA matrix
plays critical role in controlled release of active ingredient into the
plasma circulation.
The exanatide ER had similar extended-release behavior (31)
like the double-walled microspheres (DWMS) (27) of exenatide IR
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using model based approach, in which three transit compartments
were utilized to describe drug release and to evaluate drug ab-
sorption in rats. During an exploratory analysis in current study,
transit compartment approach was also utilized to describe release
of exenatide ER from PLGA matrix in clinical trials with multiple
dosing regimens. Microsphere represented the virtualcompartment (Dose (s.c)) in which a large number of drug mole-
cules were stored and the ﬁrst to fourth transit compartments
represented the different distribution compartments into which
different fractions of drug molecules were ﬂowing. When a fraction
of the drug molecules were distributed into the ﬁrst transit
compartment and then transited to the next compartment until the
fourth transit compartment. By that analogy, the reminder of the
H. Li et al. / Journal of Pharmacological Sciences 127 (2015) 170e180 179drug molecules were distributed into the fourth transit compart-
ment and quickly absorbed into central compartment. Several
transit compartments were investigated to link virtual dosing
compartment to absorption compartment, whereas four transit
compartments adequately characterized the transient burst release
within 2e2.5 h and the following steady state phase of drug plasma
concentrations after 6e7 weeks in clinical trials.
Due to exenatide IR exhibiting TMDD in various species (18), the
general TMDD approach delineating GLP-1R-binding drug dispo-
sitionwas proposed to characterize the concentration-time proﬁles
of exenatide ER in clinical trials. Results have indicated that the PK/
PD model with two-compartment and TMDD could improve the
ﬁtness of PK/PD data in the present study compared with PK/PD
model only with two-compartment (data not shown). The target
mediated PK model well descried human PK proﬁles and yielded
parameter estimates with reasonable %R.S.E. Owing to TMDD of
exenatide ER, its clearance was smaller than that of exenatide IR or
reported values (6) of exenatide IR in clinical trials.
Pharmacodynamics: Although diverse mathematical models
have been developed to quantitatively describe the PD properties of
exenatide (18,32e34), quantitative PD model with two pharma-
cological indexes of FPG and HbA1c for exenatide ER was not re-
ported. Type 2 diabetes disease progression is associated with
worsening glycemic control in the clinic (35) and quantitative
modeling of disease progression can improve the understanding of
disease and drug efﬁcacy (32). The information on average HbA1c
change is available to further evaluate the patient status of type 2
diabetes, and an increase of 0.2% HbA1c per year has reﬂected the
rate of disease progression of patients (36).
In our study, two indirect response models (Eqs. (10) and (11))
were proposed to ﬁt disease progressions with FPG and HbA1c data
in clinical trials (Fig. 1), it was hypothesized that exenatide plasma
concentrations directly regulated the loss of FPG (Eq. (10)) and
indirectly reduced the levels of HbA1c in patients with T2DM; the
FPG in turn directly affected the levels of HbA1c (Eq. (11)). The
inﬂuences of exenatide on the changes of FPG could be easily
detected in a short period, whereas the impacts of exenatide on the
changes of HbA1c were slowly determined when compared with
FPG.
For pharmacological indexes of FPG and HbA1c, the EC50G
(15 pmol/L) estimated from PK/PD model was close to the reported
value of 13.6 pmol/L (56.8 pg/mL) (11). In chronic treatment pro-
cess, the plasma concentrations of exenatide ER 2.0 mg have
reached EC80G (60 pmol/L) with 80% of maximum reduction
response in FPG and sustained the steady state concentration
(71.1 pmol/L) (4) after 7 weeks. These ﬁndings indicated that exe-
natide ER 2.0 mg once weekly in clinical treatment was an optimal
treatment regimen. The maximum glucose reduction response was
35% of baseline (167.1 mg/dl) (11), that is, 58.5 mg/dl which was
close to 57 mg/dl estimated from exposureeresponse modeling
(11). At the same time, the maximum HbA1c reduction response
was 24.9% of baseline (8.3%), that is, 2.1%, which was also close to
the reported value (mean ± SE: 1.7 ± 0.3) (9).
In clinical disease treatment, using the higher loading dose in
initial period can help the analyte approaching plasma concentra-
tion in a known therapeutic windowand improve treatment effects
for patients as quickly as possible. In this study, a hybrid PK/PD
model was successfully developed and utilized to optimize the
clinical dosing regimens for treatment of T2DM disease, which
further shortened the time of exenatide ER reaching mean steady
state concentration (71.7 pmol/L) or EC80 before 6e7 weeks and
improved the efﬁcacy (FPG and HbA1c) or changed the disease
progression of diabetes patients. The PK and safety effects of single
dose subcutaneous administration of exenatide ER (2.5, 5, 7 and
10 mg) were assessed over a period of 12 weeks with T2DMpatients (11), which has conﬁrmed that 4 doses had similar release
proﬁles over 4-fold dose range, and single doses of 5, 7 and 10 mg
resulted in plasma concentrations above the known minimally
effective concentrations of 50 pg/mL or 11.9 pmol/L to lower FPG
(37). ThroughMonte Carlo model simulations, single doses of 5 and
7.5 mg appropriately selected as higher loading doses at the ﬁrst 3
weeks were administrated to T2DM patients with different injec-
tion intervals comparedwith population prediction of 2.0mg at 30-
week treatment or currently used clinical treatment regimen (4).
In summary, we have conducted a MBMA to describe PK/PD
proﬁles of exenatide ER in patients with T2DM. This is the ﬁrst
target mediated population PK/PD study for exenatide ER in clinical
trials. Overall, this hybrid PK/PD model with 4 transit compart-
ments, GLP-1R mediated drug disposition and two indirect
response models could adequately ﬁt the PK/PD data of exenatide
ER 0.8 and 2.0 mg doses through multiple dosing regimens in
clinical trials. This hybrid PK/PDmodel was used to optimize dosing
regimens of exenatide ER, and single higher loading doses of 7.5
and 5 mg with different injection intervals were appropriately
selected through model simulation. Utilization of higher loading
doses of 7.5 and 5 mg at the ﬁrst 3 weeks would improve the PK
proﬁles and treatment effects of T2DM patients in the clinical
treatment.Disclosures
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